Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).
- Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).
- Findings also demonstrated treatment with Zeposia resulted in low rates of progression independent relapse activity (PIRA) and relapse-associated worsening (RAW), key drivers of disease progression and permanent disability in multiple sclerosis.
- “These new data underscore Zeposia’s potential to delay disease progression and improve cognitive function, especially in individuals with early relapsing multiple sclerosis,” said Roland Chen, MD , senior vice president and head, Immunology, Cardiovascular and Neuroscience Development, Bristol Myers Squibb.
- “With our focus on transformational science, we remain deeply committed to finding solutions to elevate care for the multiple sclerosis community.”
Bristol Myers Squibb thanks the patients and investigators who participated in the Zeposia clinical trials.